Products
Latest Partnered Companies
Projects
Estimated Cost :
$14 Million
Cascade Chemistry Plans for Expansion of cGMP Pharmaceutical Manufacturing Capacity
Cascade Chemistry invests $14 million for construction of new facilities designed to increase
Estimated Cost :
-
Bristol Myers Squibb to invest in New Cell Therapy Manufacturing facility in Massachusetts, USA
Construction is underway for a new cell therapy manufacturing facility in Devens, Mass., a part of Bristol Myers Squibb’s
Estimated Cost :
-
Marker Therapeutics Plans to Construct New Manufacturing Facility in Texas
Marker Therapeutics plans to construct a new manufacturing facility to support clinical development of MultiTAA-Specific T cell therapy
Estimated Cost :
US$715 million
Merck Invests US$715 million in New Facility at Madison,USA
Merck with an investment of US$715 million plans for the expansion of Antibody-drug Conjugates (ADC) manufacturing. The new manufacturing facility wil...
Press Release
Lee’s Pharmaceutical Announces its Anti-PD-L1 Antibody Socazolimab, Licensed From Sorrento Therapeutics, Receives Clearance to Start Phase 3 Trial as a First-line Treatment
China Oncology Focus Limited (COF), an affiliate of Lee's Pharmaceutical Holdings Limited (Lee's Pharm, HKEX: 950) announced that its anti-PD-L1 antibody, Socazolimab, licensed from Sorrento to COF for the greater China territory, has been cleared to begin a multicenter
Hyloris’ Partner AFT Pharmaceuticals Signs Licensing Agreement with Aguettant for Maxigesic® IV in Eight European Markets
Hyloris Pharmaceuticals SA, a specialty biopharma company committed to bringing innovative treatments that offer added value to underserved patient populations, announces that its partner AFT Pharmaceuticals (“AFT”) has signed an exclusive licensing agreement with Aguettant for Maxigesic IV
Foresee Pharmaceuticals Enters Exclusive License Agreement with Intas Pharmaceuticals for Commercialization in the United States
Foresee Pharmaceuticals announced that it has entered into an exclusive license agreement with Intas Pharmaceuticals ("Intas") for the US commercialization of Foresee's novel FP-001 program, Leuprolide Mesylate Injectable Suspension (LMIS) ready-to-use subcutaneous 6-month and 3-month depot formulations
Luminex Receives FDA Emergency Use Authorization and CE Mark for Expanded NxTAG® Respiratory Panel Test Including SARS-CoV-2
Luminex Corporation announced that it has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for a new expanded version of its NxTAG® Respiratory Pathogen Panel (RPP) that includes the SARS-CoV-2 virus for high-throughput respiratory testing.
Events
8th World Congress and Exhibition on Antibiotics and Antibiotic Resistance
Articles
A Complete Guide on Blister Packaging Machine
Packaging machinery is one of the vital equipment in the pharmaceutical industry, food processing, and chemical
Nanotechnology in Drug Delivery to Eyes, Skin, and Wounds Via Topical Route
One of the most favored courses for administering medications to eyes, skin, and wounds is the topical route. The principle objective for this
An Overview - Active Pharmaceutical Ingredient (API)
Active Pharmaceutical Ingredient (API) is the term used to refer to the biologically active component of a drug product
Next-Generation Biological Therapeutics Discovery & Development
Focus on drug discovery and development has shifted away from small to large, complex molecular entities
AI, Big Data to Have \'Greatest Technology Impact\' in Pharma Industry in 2019
According to a recent report by GlobalData, Artificial Intelligence and Big Data will revolutionize the Pharma industry
Expert Talk
Testimonials
I have read it with interest. I think it could be of interest to managers and professionals in Asia's Pharma companies as well as global companies that wish to learn more about how to do business--from R&D to marketing-in Asia.
Baoping Wang - Research Director
Novo Nordisk (China) R&D Centre
Advertisements
See your banner here...
.jpg)
Thank you for contacting us. One of our support staff will get in touch with you shortly.
Happy Surfing!
Regards,
Client Success Team (CRM),
